Physician profile
Ijeoma Nwuju
NPI 1902224959
$600,990.96
in general payments reported to CMS, 2019-2025
11 companies · $421K in 2025
The $421K reported for 2025 was more than what 99% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,725 · 2020: $1,735 · 2021: $4,893 · 2022: $4,510 · 2023: $40.22 · 2024: $165K · 2025: $421K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $585K · Travel and Lodging: $915 · Food and Beverage: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $584,946.90 |
| Travel and Lodging | $915.49 |
| Food and Beverage | $266.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $585,090.80 | 2022-2025 | |
| Supreme Orthopedic Systems, LLC | $12,514.48 | 2019-2022 | |
| Triad Life Sciences INC. | $1,767.52 | 2022 | |
| Lifenet Health | $1,126.93 | 2025 | Theragenesis Wound Matrix |
| Organogenesis INC. | $167.95 | 2021-2022 | |
| Horizon Therapeutics Plc | $124.84 | 2019 | |
| Smith+Nephew, INC. | $51.92 | 2022 | |
| Paratek Pharmaceuticals, INC. | $49.98 | 2022-2024 | Nuzyra |
| Cashflow Solutions, LLC | $43.84 | 2022-2023 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
| Bioventus LLC | $36.44 | 2020-2021 | |
| Stryker Corporation | $16.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ijeoma Nwuju listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.